Research note · 2026-07-15 · 24 to 48 months horizon · conviction: Medium
LLY · Eli Lilly
LONG
Selling the decade's biggest new drug market at a widening lead — the obesity TAM is early, under-penetrated, and Lilly's pipeline extends the moat.
Situation
Eli Lilly is a leader in the incretin (GLP-1) class, with obesity and diabetes drugs addressing a market many estimate above $100B. Revenue is growing 30%+, and the pipeline runs well beyond incretins into oral GLP-1, Alzheimer's, and immunology.
Complication
The stock trades at a large premium (40x+ earnings), so the thesis demands sustained hyper-growth, a successful manufacturing scale-up, and holding share against Novo Nordisk and coming entrants. Any supply, safety, or reimbursement stumble is punished hard.
Thesis
1. The obesity market is early and under-penetrated
Only a small fraction of eligible patients are treated today. Cardiovascular, sleep-apnea, and kidney label expansions convert obesity treatment from cosmetic to reimbursed chronic care, widening the funnel structurally.
2. Lilly is widening, not defending, the moat
Oral GLP-1 (orforglipron) and next-generation molecules (retatrutide) push efficacy and convenience ahead of the field, while the manufacturing capex is itself a barrier to entry, not just a cost line.
3. It is more than incretins
A genuine multi-franchise pipeline — Alzheimer's, immunology — gives optionality the market underweights while it fixates on GLP-1. The base business de-risks the premium.
Catalysts
| Window | Event |
|---|---|
| 6 to 18 months | Oral GLP-1 trial readouts and launch milestones |
| 12 to 36 months | Label expansions (cardiovascular, sleep apnea, chronic kidney disease) |
| 6 to 24 months | New manufacturing capacity coming online, easing the supply constraint |
Risks and mitigants
| Risk | Mitigant / monitor |
|---|---|
| A premium multiple that de-rates on any growth wobble | Conviction deliberately set to Medium and sized accordingly; 30%+ growth cushions even a meaningful multiple contraction |
| Share loss to Novo Nordisk or new entrants | Lilly's efficacy data and oral pipeline currently lead; the KPI to watch is quarterly incretin revenue share |
| Manufacturing or supply constraints capping the ramp | Capacity build-out is the explicit catalyst to monitor — a bottleneck would be visible in gross-to-net and supply commentary before it hits results |
What I am watching
- Mounjaro / Zepbound revenue growth (quarterly)
- Oral GLP-1 trial readouts and filings
- Gross-to-net and supply commentary
- New indication approvals
Valuation
Comparable multiples
| Ticker | Company | P/E | EV/EBITDA | Rev growth | Note |
|---|---|---|---|---|---|
| LLY | Eli Lilly | 45 | 34 | +30% | Premium for incretin leadership and pipeline optionality |
| NVO | Novo Nordisk | 30 | 22 | +22% | The other incretin leader — direct competitive read |
| MRK | Merck | 15 | 11 | +6% | Large-cap pharma baseline without the GLP-1 growth |
| PFE | Pfizer | 11 | 9 | +2% | Illustrates the multiple on ex-growth pharma |
Author estimates as of July 15, 2026 — verify against live data before relying on multiples.
Price targets
Interactive DCF
Sensitivity: implied value per share (WACC × terminal growth)
| WACC \ g | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|
| 7.0% | $527 | $581 | $648 | $735 |
| 7.5% | $474 | $517 | $570 | $636 |
| 8.0% | $429 | $465 | $508 | $560 |
| 8.5% | $392 | $422 | $456 | $498 |
| 9.0% | $360 | $385 | $414 | $448 |
| 9.5% | $332 | $353 | $378 | $406 |
| 10.0% | $308 | $326 | $347 | $371 |
Green cells imply 5%+ upside to the current price, red cells 5%+ downside. Adjust the inputs above; the grid recomputes live.